Victory Capital Management Inc Collegium Pharmaceutical, Inc Transaction History

Victory Capital Management Inc

  • $92 Billion
  • Q1 2025

A detailed history of Victory Capital Management Inc transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Victory Capital Management Inc holds 498,713 shares of COLL stock, worth $14.6 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
498,713
Previous 559,536 10.87%
Holding current value
$14.6 Million
Previous $16 Million 7.14%
% of portfolio
0.02%
Previous 0.02%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 02, 2025
SELL
$28.04 - $33.91 $1.71 Million - $2.06 Million
-60,823 Reduced 10.87%
498,713 $14.9 Million
Q4 2024

Feb 06, 2025
SELL
$28.61 - $41.86 $4.32 Million - $6.33 Million
-151,152 Reduced 21.27%
559,536 $16 Million
Q3 2024

Nov 05, 2024
BUY
$31.4 - $39.07 $6.78 Million - $8.43 Million
215,874 Added 43.63%
710,688 $27.5 Million
Q2 2024

Aug 05, 2024
SELL
$31.36 - $39.99 $976,832 - $1.25 Million
-31,149 Reduced 5.92%
494,814 $15.9 Million
Q1 2024

May 03, 2024
SELL
$31.23 - $40.91 $6.16 Million - $8.07 Million
-197,334 Reduced 27.28%
525,963 $20.4 Million
Q4 2023

Feb 05, 2024
SELL
$21.16 - $30.8 $528,449 - $769,199
-24,974 Reduced 3.34%
723,297 $22.3 Million
Q3 2023

Nov 06, 2023
SELL
$21.23 - $24.28 $633,205 - $724,175
-29,826 Reduced 3.83%
748,271 $16.7 Million
Q2 2023

Jul 27, 2023
BUY
$21.06 - $24.0 $14.4 Million - $16.4 Million
681,814 Added 708.14%
778,097 $16.7 Million
Q1 2023

May 02, 2023
SELL
$23.0 - $29.88 $306,222 - $397,822
-13,314 Reduced 12.15%
96,283 $2.31 Million
Q4 2022

Feb 10, 2023
SELL
$16.14 - $23.55 $77,133 - $112,545
-4,779 Reduced 4.18%
109,597 $2.54 Million
Q4 2022

Feb 09, 2023
SELL
$16.14 - $23.55 $218,374 - $318,631
-13,530 Reduced 10.58%
114,376 $2.65 Million
Q3 2022

Nov 02, 2022
SELL
$15.46 - $20.1 $74,115 - $96,359
-4,794 Reduced 3.61%
127,906 $2.05 Million
Q2 2022

Aug 01, 2022
BUY
$14.22 - $20.88 $329,463 - $483,768
23,169 Added 21.15%
132,700 $2.35 Million
Q1 2022

May 04, 2022
SELL
$17.2 - $22.5 $41,090 - $53,752
-2,389 Reduced 2.13%
109,531 $1.95 Million
Q3 2021

Nov 02, 2021
BUY
$17.75 - $25.39 $178,139 - $254,814
10,036 Added 9.85%
111,920 $2.21 Million
Q2 2021

Aug 03, 2021
BUY
$21.74 - $25.28 $960,451 - $1.12 Million
44,179 Added 76.56%
101,884 $2.41 Million
Q1 2021

May 04, 2021
BUY
$19.25 - $26.1 $125,644 - $170,354
6,527 Added 12.75%
57,705 $1.37 Million
Q4 2020

Feb 01, 2021
BUY
$17.83 - $22.29 $47,445 - $59,313
2,661 Added 5.48%
51,178 $1.03 Million
Q3 2020

Nov 09, 2020
SELL
$15.78 - $20.82 $130,689 - $172,431
-8,282 Reduced 14.58%
48,517 $1.01 Million
Q2 2020

Aug 07, 2020
BUY
$15.49 - $23.51 $122,990 - $186,669
7,940 Added 16.25%
56,799 $994,000
Q1 2020

May 04, 2020
BUY
$13.89 - $25.45 $139,900 - $256,332
10,072 Added 25.97%
48,859 $798,000
Q4 2019

Feb 06, 2020
SELL
$10.7 - $22.24 $28,718 - $59,692
-2,684 Reduced 6.47%
38,787 $798,000
Q4 2019

Feb 04, 2020
SELL
$10.7 - $22.24 $18,885 - $39,253
-1,765 Reduced 4.08%
41,471 $834,000
Q3 2019

Nov 12, 2019
BUY
$10.16 - $13.28 $427,217 - $558,410
42,049 Added 3542.46%
43,236 $496,000
Q4 2018

Feb 05, 2019
SELL
$14.78 - $19.68 $3,340 - $4,447
-226 Reduced 15.99%
1,187 $20,000
Q3 2018

Nov 01, 2018
BUY
$14.16 - $24.3 $2,633 - $4,519
186 Added 15.16%
1,413 $21,000
Q2 2018

Aug 02, 2018
BUY
$21.79 - $28.29 $26,736 - $34,711
1,227 New
1,227 $29,000

Others Institutions Holding COLL

# of Institutions
253
Shares Held
37.1M
Call Options Held
61.1K
Put Options Held
5.8K
View Full List

About COLLEGIUM PHARMACEUTICAL, INC

COLL Quotes by TradingView
  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email